For BAT, this has been a pivotal year, as we published the 6-month results from our ground-breaking one-year study of our flagship THP, glo. This was the biggest study ever undertaken by BAT and makes a significant contribution to the evidence-base for this category.
We were excited to see the results recorded at the 6-month mark showing that switching completely to glo resulted in statistically significant changes across a range of biomarkers of exposure and biomarkers of potential harm, compared with continuing to smoke.
It is this sharing of information that is a key component of Tobacco Harm Reduction and helps smokers find alternative products that meet their preferences and offer comparable satisfaction in nicotine delivery, use and sensorial aspects.
This recognises the potential benefits of quitting smoking while acknowledging the fact that some smokers will choose to continue to use tobacco and/or nicotine.
1. A significant favourable difference in biomarkers
2. Similarity of effect size compared with cessation,
12-month clinical study on glo
Results recorded at the 6-month mark of the 12-month study showed that switching completely to glo resulted in statistically significant changes across a range of biomarkers of exposure and biomarkers of potential harm, compared with continuing to smoke. For most biomarkers measured, the reductions seen in people using glo were similar to those in participants who stopped smoking completely2. These data were published in the journal Internal and Emergency Medicine.
BAT’s Director of Scientific Research, Dr David O’Reilly, proudly presented the data at scientific media events in Russia and Romania earlier this year.
“The study shows that smokers switching to glo can reduce their exposure to certain toxicants, which reduces their risk of developing certain smoking related diseases. To have shown a significant reduction in measures of biomarkers of potential harm, some comparable to quitting completely, is very encouraging and provides further scientific substantiation of the harm reduction potential of glo and how it supports our ambition to build A Better Tomorrow™ by reducing the health impact of our business.”
The results from the full 12-month study will be published in 2022.
* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.
**This is a comparison between the smoke from a combusted scientific standard reference cigarette (approximately 9mg tar) and vapour from heated tobacco in glo, in terms of the average of the 9 harmful components the World Health Organization recommends to reduce in cigarette smoke.
† Our products as sold in the US, including Vuse, Velo, Grizzly, Kodiak, and Camel Snus, are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance.
1. Institute of Medicine. 2012. Scientific Standards for Studies on Modified Risk Tobacco Products. Washington, DC: The National Academies Press. - VIEW LINK
2. Gale, N., McEwan, M., Camacho, O.M. et al. Changes in biomarkers after 180 days of tobacco heating product use: a randomised trial. Intern Emerg Med 16, 2201–2212 (2021). - VIEW LINK